Last reviewed · How we verify
CT-P47
CT-P47 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.
CT-P47 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).
At a glance
| Generic name | CT-P47 |
|---|---|
| Sponsor | Celltrion |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CT-P47 is a PD-L1 checkpoint inhibitor developed as a biosimilar or novel anti-PD-L1 therapeutic. By blocking the PD-L1/PD-1 axis, it prevents tumor cells from suppressing T-cell mediated immunity, thereby reactivating the body's anti-tumor immune response. This mechanism is used to treat various solid tumors and hematologic malignancies.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (under investigation in Phase 3)
Common side effects
- Fatigue
- Infusion-related reactions
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Diarrhea
- Rash
Key clinical trials
- A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis (PHASE3)
- Compare the Auto-injector and Pre-filled Syringe of CT-P47 in Healthy Subjects (PHASE1)
- A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid Arthritis (PHASE3)
- A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |